Tozorakimab Market Insights

Key Factors Driving Tozorakimab Growth

1) Massive COPD market opportunity with persistent unmet need

COPD affects ~390–400 million people globally and remains the 3rd leading cause of death worldwide, according to WHO/AstraZeneca. Even with triple inhaled therapy (ICS/LABA/LAMA), >50% of patients still experience exacerbations, which drive hospitalizations and mortality. This creates a very large biologic opportunity, especially since treatment innovation in broad COPD populations has historically been limited.

2) First IL-33 biologic to show consistent Phase III success

This is the biggest growth catalyst. In March 2026, AstraZeneca announced that the Phase III OBERON and TITANIA trials (n=2,306 combined) met their primary endpoints by significantly reducing annualized moderate-to-severe COPD exacerbations in both:

• Former smokers (primary population)

• Overall population (including current smokers)

This made Tozorakimab the first IL-33-targeting biologic to show replicated Phase III success in COPD, substantially de-risking approval potential.

3) Additional Phase III MIRANDA win strengthens regulatory confidence

In April 2026, the Phase III MIRANDA trial (n=1,454) also met its primary endpoint.

Key highlights:

• Statistically significant reduction in annualized moderate-to-severe exacerbations

• Worked across all eosinophil levels

• Effective across all stages of lung-function severity

• Included both current and former smokers

Three positive pivotal trials significantly improve regulatory approval probability versus respiratory drugs that rely on only one positive study.

 

4) Broader eligible population than current biologics

Unlike Dupixent or Nucala, which largely target eosinophilic/type-2 inflammation subsets, Tozorakimab showed efficacy irrespective of blood eosinophil count.

This is commercially important because:

• Many COPD patients do not qualify for eosinophil-targeted biologics

• Broader labeling could expand prescribing significantly

• May become a preferred biologic option for general COPD exacerbation prevention.

 

Tozorakimab Recent Developments

In April 2026, AstraZeneca announced the Positive high-level results from the pivotal Phase III MIRANDA trial showed potential first-in-class tozorakimab demonstrated a statistically significant and clinically meaningful reduction in the annualised rate of moderate-to-severe COPD exacerbations in the primary population of former smokers and in the overall population, which included former and current smokers, and patients across all blood eosinophil* counts and all stages of lung function severity. 

“Tozorakimab Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of Tozorakimab for potential indication like Chronic obstructive pulmonary disease, Respiratory insufficiency, and Asthma in the 7MM. A detailed picture of Tozorakimab’s existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the Tozorakimab for potential indications. The Tozorakimab market report provides insights about Tozorakimab’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current Tozorakimab performance, future market assessments inclusive of the Tozorakimab market forecast analysis for potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of Tozorakimab sales forecasts, along with factors driving its market.

 

Tozorakimab Drug Summary

Tozorakimab is an investigational human monoclonal antibody developed by AstraZeneca that targets Interleukin-33, an epithelial-derived alarmin involved in airway inflammation and immune activation. By neutralizing both reduced and oxidized forms of IL-33, tozorakimab is designed to inhibit downstream inflammatory pathways associated with exacerbations and lung damage in respiratory diseases. It is being developed primarily for Chronic Obstructive Pulmonary Disease, where it has shown potential to reduce exacerbations and improve outcomes in patients with persistent inflammation despite standard therapies. The drug has also been explored in acute respiratory settings, including COVID-19-related lung injury, reflecting its broader anti-inflammatory potential. Currently in advanced clinical development, tozorakimab is considered a promising next-generation biologic targeting upstream inflammation in COPD. The report provides Tozorakimab’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

 

Scope of the Tozorakimab Market Report

The report provides insights into:

• A comprehensive product overview including the Tozorakimab MoA, description, dosage and administration, research and development activities in potential indication like Chronic obstructive pulmonary disease, Respiratory insufficiency, and Asthma.

• Elaborated details on Tozorakimab regulatory milestones and other development activities have been provided in Tozorakimab market report.

• The report also highlights Tozorakimab‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.

• The Tozorakimab market report also covers the patents information, generic entry and impact on cost cut.

• The Tozorakimab market report contains current and forecasted Tozorakimab sales for potential indications till 2034.

• Comprehensive coverage of the late-stage emerging therapies for respective indications.

• The Tozorakimab market report also features the SWOT analysis with analyst views for Tozorakimab in potential indications.

 

Methodology

The Tozorakimab market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

 

Tozorakimab Analytical Perspective by DelveInsight

• In-depth Tozorakimab Market Assessment

This Tozorakimab sales market forecast report provides a detailed market assessment of Tozorakimab for potential indication like Chronic obstructive pulmonary disease, Respiratory insufficiency, and Asthma in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted Tozorakimab sales data uptil 2034.

• Tozorakimab Clinical Assessment

The Tozorakimab market report provides the clinical trials information of Tozorakimab for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

Tozorakimab Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

Tozorakimab Market Potential & Revenue Forecast

• Projected market size for the Tozorakimab and its key indications

• Estimated Tozorakimab sales potential (Tozorakimab peak sales forecasts)

• Tozorakimab Pricing strategies and reimbursement landscape

Tozorakimab Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)

• Tozorakimab Market positioning compared to existing treatments

• Tozorakimab Strengths & weaknesses relative to competitors

Tozorakimab Regulatory & Commercial Milestones

• Tozorakimab Key regulatory approvals & expected launch timelines

• Commercial partnerships, licensing deals, and M&A activity

Tozorakimab Clinical Differentiation

• Tozorakimab Efficacy & safety advantages over existing drugs

• Tozorakimab Unique selling points

 

Tozorakimab Market Report Highlights

• In the coming years, the Tozorakimab market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.

• The Tozorakimab companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Tozorakimab’s dominance.

• Other emerging products for Chronic obstructive pulmonary disease, Respiratory insufficiency, and Asthma are expected to give tough market competition to Tozorakimab and launch of late-stage emerging therapies in the near future will significantly impact the market.

• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Tozorakimab in potential indications.

• Analyse Tozorakimab cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.

• Our in-depth analysis of the forecasted Tozorakimab sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of Tozorakimab in potential indications.

 

Key Questions

• What is the class of therapy, route of administration and mechanism of action of Tozorakimab? How strong is Tozorakimab’s clinical and commercial performance?

• What is Tozorakimab’s clinical trial status in each individual indications such as Chronic obstructive pulmonary disease, Respiratory insufficiency, and Asthma and study completion date?

• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Tozorakimab Manufacturers?

• What are the key designations that have been granted to Tozorakimab for potential indications? How are they going to impact Tozorakimab’s penetration in various geographies?

• What is the current and forecasted Tozorakimab market scenario for potential indications? What are the key assumptions behind the forecast?

• What are the current and forecasted sales of Tozorakimab in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan? 

• What are the other emerging products available and how are these giving competition to Tozorakimab for potential indications?

• Which are the late-stage emerging therapies under development for the treatment of potential indications?

• How cost-effective is Tozorakimab? What is the duration of therapy and what are the geographical variations in cost per patient?